Brief: KalVista Pharma Says Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy

Kalvista Pharmaceuticals

13/02/2024 11:35

Feb 13 (Reuters) - Kalvista Pharmaceuticals Inc
 KALV.O :
    * KALVISTA PHARMACEUTICALS INC: ON TRACK FOR SUBMISSION OF
NEW
DRUG APPLICATION TO U.S. FDA IN FIRST HALF OF 2024
    * KALVISTA PHARMACEUTICALS INC - SAFETY PROFILE COMPARABLE
TO
PLACEBO
    * KALVISTA PHARMACEUTICALS INC - SEBETRALSTAT 300 MG
ACHIEVED
BEGINNING OF SYMPTOM RELIEF IN 1.6 HOURS
    * KALVISTA PHARMACEUTICALS REPORTS PHASE 3 KONFIDENT TRIAL
MEETS
ALL ENDPOINTS FOR SEBETRALSTAT AS FIRST ORAL ON-DEMAND THERAPY
FOR HEREDITARY ANGIOEDEMA
    * KALVISTA PHARMACEUTICALS INC - SEBETRALSTAT 300 MG
ACHIEVED
BEGINNING OF SYMPTOM RELIEF IN 1.6 HOURS

Source text for Eikon:  ID:nBw31XTJha 
Further company coverage:  KALV.O 

 ((Reuters.Briefs@thomsonreuters.com;))